The complex interactions between cancer cells and their surrounding stromal microenvironment play important roles in tumor initiation and progression and represent viable targets for therapeutic intervention. Here, we propose a concept of common target perturbation (CTP). CTP acts simultaneously on the same target in both the tumor and its stroma that generates a bilateral disruption for potentially improved cancer therapy. To employ this concept, we design a systems biology strategy by combining experiment and computation to identify potential common target.
INTRODUCTION
Tumors are mixtures comprising both neoplastic cells and stromal cells. It is becoming increasingly evident that the occurrence and development of tumors not only depend on the factors intrinsic to the tumor itself, but also require support from the stromal microenvironment surrounding the tumor (1) . The complex interactions among tumor cells and the various types of cells and matrix elements within the microenvironment play important roles in cancer initiation, progression and invasion. For instance, carcinoma-associated fibroblasts (CAFs) are one of the most significant cell types found within the desmoplastic stroma in many types of carcinomas. CAFs interact with cancer cells through various signaling molecules, which can significantly affect cancer proliferation, survival, motility and invasion (2) (3) (4) .
Decades of cancer research have identified a number of genes for anticancer treatment, from cancer cells as well as from stroma cells. The unilateral perturbation (ULP) strategy targeting these genes in either the tumor or its microenvironment alone has brought dramatic therapeutic advances and substantially improved the lives of cancer patients (5) . However, cancer is extremely complex and the ULP treatment is only partially effective (6) . Another combinatorial strategy, the bilateral perturbation (BLP), which targets both tumor and its microenvironment, has emerged as a promising candidate for cancer therapy by fighting against cancer as a whole system (7) (8) (9) . However, the implementation of the BLP strategy is challenging. One bottleneck is the identification of multiple effective targets that each works in the tumor cells and the stromal cells.
It has been estimated that 5% to 10% of human genes may contribute to (11) . The huge gap suggests that a large number of cancer genes remain to be identified. Although traditional gene mapping approaches, such as linkage analysis and association studies, have been proved to be powerful tools for disease gene discovery, they suffer from limited resolution to gene localization and great time and labor expense (12) . In recent years, with the progress of high-throughput techniques and computational methods, systems biology approaches are being exploited to the discovery of disease genes and prognostic biomarkers (13) (14) (15) (16) . Systems biology provides unique tools to prioritize disease-related genes and identify potential target for cancer treatment.
In the present study, we introduced another concept called common target perturbation (CTP), which perturbs the same target in the cancerous epithelium and its adjacent stroma simultaneously to inhibit tumor growth. Without the multiple-targeting or potential complement between cancer and stroma, CTP provides a promise for improved cancer therapy. Key of the CTP concept is to identify effective tumor-stroma common targets, whose perturbation will be destructive for tumors. We test our CTP concept by performing simultaneous perturbation of oral cancerous epithelia cells and their adjacent CAFs using oral squamous cell carcinoma (OSCC) as a model system.
We develop a systems biology strategy that combines experiment and computation for identification of the epithelial-mesenchymal common targets (EMCTs). These progressive organic cycles identified TβRIII (also known as TGFBR3) as a potential
EMCT. In vivo assessment shows that the simultaneous perturbation of TβRIII in the cancerous epithelial cells and its adjacent CAFs effectively inhibited tumor growth, and that this CTP-derived treatment is more effective than the common ULP approach. 
MATERIALS AND METHODS
Bioinformatics analysis. The cancer signature genes identified from samples of twenty cancer types were obtained from the work of Lu et al. (17) . The human PPI data were downloaded from the Human Protein Reference Database. Three gene expression datasets (GSE6631 (36), GSE3524 (37) , and GSE9638 (38)) of oral cavity tumors were downloaded from the Gene Expression Omnibus (GEO) database.
Functional annotation of SPP1Net was completed using the DAVID webserver (39), and SPP1Net was drawn using Cytoscape (40) .
Neighborhood analysis.
To quantify the extent of gene expression changes in the cancerous epithelium and stroma with respect to their normal counterparts, we introduced a score: f es raw . The f es raw score is defined as the absolute value of the product of the gene expression fold changes in the cancerous epithelium and stroma with respect to their normal counterparts. The higher f es raw score of a gene will represent a higher extent of expression changes in both the cancerous epithelium and stroma, and thus a higher probability as an effective EMCT. We scaled the f es raw score from 0 to 1 on the basis of the estimated cumulative density function derived from kernel-density estimation, so that the scaled f es raw score of a gene, denoted as f es , is the estimated percentage of genes with actual f es raw scores below this gene.
For a subnetwork S of k genes, we produced an aggregate score f S defined as the mean f es of all genes in the subnetwork:
To determine whether the f S score of a subnetwork is higher than expected, we randomly sampled gene sets of size k independently of the network and computed their f S scores. We then used these to derive estimates for the score mean μ k and standard deviation σ k . Using these estimates, the normalized subnet score Z S is computed as:
Based on the above scoring scheme, a Monte Carlo approach was implemented to search for a high-scoring subnetwork around SPP1. The procedure starts from SPP1 and proceeds by moving along the edges of the network to maximize Z S . Moves are accepted according to the Metropolis criteria (41) . Briefly, at every time step one neighboring node of the current subnetwork is picked with probability proportional to its f es score. If the Z S score change (ΔZ S ) before and after the addition of the gene into the current subnetwork is positive, the addition of the gene is accepted. Otherwise, the addition is accepted with probability P = exp(ΔZ S /T i ), where T i is the current temperature for simulated annealing. 
RESULTS

Common Target Perturbation (CTP) Guided Epithelial-Mesenchymal Common
Target (EMCT) Discovery Strategy
CTP concept hypothesizes that, in the development of cancer, epithelium and stroma share some important factors, and simultaneous attack on these common factors in both the epithelium and its adjacent stroma may augment the destruction of tumors.
The key in the CTP-guided cancer therapy is the identification of effective common targets. If a gene exhibits significant expression changes in both the cancerous epithelium and its associated stroma compared to their normal counterparts, it would be important for cancer development, thus likely to be an EMCT. In addition, proteins rarely act in isolation. The biological functions of the proteins are implemented by interacting with other proteins, therefore each gene has its own topological characters.
Combining both features, we defined an EMCT discovery strategy to screen highly potential EMCTs by evaluating gene expression behavior and topological significance in the context of the human protein-protein interaction (PPI) network.
This EMCT identification strategy is also developed to combine a series of experiments and computations into progressive organic cycles. In each cycle, computation-guided experiments and experiment-corrected computations will be performed to generate multiple feedbacks. Particularly, this feedback strategy allows different predictions to be proposed in each cycle, thus providing a flexible adjustment of candidates for experiments. Here, we implemented a prototypic, two-cycle procedure (Fig. 1) . The first cycle identifies candidates important for cancer knowledge, will finally determine the candidate as EMCT. Top ranked EMCT(s) will then be implemented into experimental verification and the final effective EMCT(s) will be confirmed.
Prediction of SPP1 as an EMCT Seed
A qualified seed gene should be heavily involved in cancer development. For example, genes that are dysregulated in many types of cancers will have a high likelihood of being involved in carcinogenesis. We adopted a two-step procedure to predict seeds. First, we analyzed the publicly available expression data on tumors to identify potential oral cancer-related genes that are over-or under-expressed in oral cancer; Second, considering that few data on oral stroma are available, we profiled the gene expression in oral CAFs and normal fibroblasts (NFs), and kept only those oral cancer-related genes that were differentially expressed in CAFs with respect to NFs as potential seeds.
To achieve a high success rate of prediction, we started from a list of reported 187 cancer signature genes, which were dysregulated in 20 types of cancers (17) . We first ranked these genes by quantifying their importance in the context of the human PPI 
13 generated a list of 24 genes (S24) (Supplementary Fig.1 ). Because oral cancer was not included in the selection of the original 187 genes, we further refined seed genes that show the common trend of expression changes in oral cancer as in other cancer types. We analyzed three public oral cancer data sets and kept 16 genes (S16) (Supplementary Fig.1 ).
To identify important genes functioning in the stroma during carcinogenesis, we collected 12 OSCC tissues and 12 normal oral tissues (TG1), from which oral CAFs and NFs (CG1) were obtained. We pooled the CAFs and NFs respectively, and measured their gene expression using microarrays. Based on our stroma expression data, seven genes (S7 out of the S16 set) differentially expressed in CAFs with respect to NFs were identified as seed predictions (Supplementary Fig.1) . Two (SPP1, FAM107A) were consistently changed in the epithelium and stroma (i.e. with the same direction of change), and five (AURKA, PRC1, CEP55, FEN1, DNMT1) were inversely changed (i.e. with opposite direction of change). This S7 set represents highly potential EMCTs, which showed significant expression changes in the cancerous epithelium and its adjacent stroma, and were important in the sense of topological centrality. Lastly, with the consideration of further treatment on the epithelium and stroma simultaneously by the same agent, we selected SPP1 for further validation, which showed changes in the same direction in both cell types.
Experimental examination confirmed the expected upregulation of SPP1 mRNA and protein in both OSCC cells and CAFs compared with their normal counterparts ( Table 1 ).
Seed Neighborhood Analysis Identifies TβRIII as an EMCT
After verifying the expression behavior of SPP1 and its close association with oral carcinogenesis, we proceeded to the second cycle of EMCT discovery to search for potential EMCT(s) that is closely interconnected around SPP1.
We introduced a score f es to quantify the extent of gene expression changes in the cancerous epithelium and stroma with respect to their normal counterparts. For a subnetwork S of k genes, we produced an aggregate score f S defined as the mean f es of all genes in the subnetwork. The final subnet score Z S is obtained by normalizing f S against the null distribution generated based on randomly sampled gene sets of size k. Based on the above scoring scheme, a Monte Carlo approach was implemented to search for a high-scoring subnetwork around SPP1 (Methods). The procedure starts Table 2 ). Members of several signaling pathways, including the TGF-β, MAPK, and ErbB signaling pathways are significantly enriched in SPP1Net.
The enrichment of members of the TGF-β pathway ranked first among all the examined signaling pathways, indicating the importance of the TGF-β pathway for epithelial-mesenchymal interaction during oral cancer development (Supplementary Table 2 ). As a top-level participant in the TGF-β pathway, TGF-β receptor III (TβRIII) had the highest f es score (0.99) in the pathway. In our previous work, we found that TβRIII was consistently downregulated in oral tumors and their adjacent stroma (19) .
The TβRIII level was suggested to be important for cancer tumorigenicity, progression, and invasion (20, 21, 22) . Although no studies of TβRIII in stromal and oral cancer have been reported, our analysis indicated TβRIII as the top-rated candidate for final EMCT experimental validation. Upon completion of this work, we got to know a recent study, which reported that TGFBRIII downregulation could result in an immunotolerant tumor microenvironment (23) .
Common Target Perturbation (CTP) of TβRIII Effectively Inhibited Tumor Growth
We first evaluated the expression level of TβRIII and confirmed the loss of TβRIII expression in both oral cancer epithelium and its adjacent stroma (Fig. 2d, 2e) Compared with the controls, the ULP groups exhibited a significantly lower cell survival rate (Fig. 3a) and colony formation efficiency (Fig. 3b) , and a moderate level of apoptosis (Fig. 3c) . These observations indicated that re-expression of TβRIII in human oral cancer cell lines decreased cancer cell proliferation.
To investigate the effect of TβRIII ULP in stromal cells, we established an oral CAF cell line re-expressing TβRIII (CAF-TβRIII) and a control cell line expressing the empty vector (CAF-GFP). Cell viability did not change significantly between the ULP and control groups (Fig. 3d) . However, the ULP group showed down-regulation of CAF markers including α-SMA (Fig. 3e) and SDF-1 (Fig. 3f) , suggesting potential structural alterations in CAF-TβRIII cells. Structural analysis showed that certain typical morphological structures, such as large spindle-like shape, intended nuclei, peripheral myofilaments and focal densities were present in the CAF and CAF-GFP cells but appeared absent in the CAF-TβRIII cells and NFs (Fig. 3g) . These results indicated that some specific ultrastructures of TβRIII ULP in CAFs have changed, which are more close to those of NFs.
After perturbation of TβRIII expression in oral cancerous epithelial cells and CAFs, we continued to explore whether CTP-targeting TβRIII in epithelium and stroma simultaneously would be more effective than the ULPs in suppressing cancer growth. To understand the biological changes in the process of TβRIII CTP, we performed further investigations. Expression of the proliferation marker Ki-67 was reduced markedly in TβRIII-perturbed groups but did not show significant difference between the ULP and the CTP groups (Fig. 4b) . The average microvascular density in TβRIII-perturbed groups was significantly lower than in the unperturbed groups.
Importantly, the CTP group had the lowest density, suggesting stronger suppression of tumor angiogenesis by TβRIII CTP (Fig. 4c) . Pathological examination of the primary tumors demonstrated that TβRIII CTP decreased tumor metastasis (Fig. 4d) .
Examination of E-cadherin expression, which correlates negatively with the potential for tumor invasion and metastasis, showed much higher level of E-cadherin in the CTP group compared with other groups (Fig. 4e) , indicating a substantial depression of invasiveness. In all, these data indicated that the superiority of TβRIII CTP over ULP in tumor suppression was caused by depression of tumor proliferation, angiogenesis, and metastasis. 
DISCUSSION
In recent years, the complex tumor-microenvironment interactions have been recognized as important contributors to the robustness of cancer (24) (25) (26) and viable targets for therapeutic intervention (8, 27, 28) . In light of the BLP combinatorial strategy (7-9), we proposed the CTP concept as a potential anticancer therapy, which has the advantage of perturbing the same target in the epithelium and its stroma simultaneously by the same agent. We developed a systems biology strategy that progressively cycles experiments and computations to discover EMCTs, the common 'fragile key points' for both the cancerous epithelium and its adjacent stroma. In the present work, a two-cycled EMCT discovery strategy was implemented to identify EMCTs in both the oral cancerous epithelia cells and their adjacent CAFs and two types of 'omics' data (expression profiling and PPIs) were used. As demonstrated, this multiple feedback strategy helps adjust experiment and computation schedule flexibly and lead to a greater success rate of target discovery. Although we only focused on TβRIII on the basis of a combination of different criteria among the predicted EMCTs, more genes can be identified. Other potential EMCTs could be validated with further work. For instance, FAM107A, identified in our cycle I analysis, is likely to be one potential target, since several recent reports have demonstrated the involvement of its interacting partner PPP2R2A in cancers (29, 30) . Besides, the framework is flexible to integrate additional 'omics' datasets from different cell types.
Our initial attempt to identify therapeutic targets by considering the tumor and its surrounding microenvironment simultaneously has shown promise on future cancer therapy.
The EMCT discovery strategy offers an important application of systems biology. Biological systems are complex systems composed of a huge number of interacting components (31) . Investigating biological systems from a systems perspective has important implications for understanding cancer and devising effective therapies (32) .
A crucial factor that underlies the efficacy of a therapeutic intervention is the robustness of the target system (24) . This ability of resistance to perturbations is attained through various mechanisms. For example, functional redundancy could enable a tumor to sustain drug attack on a biochemical pathway by finding alternative routes to escape the blockage (33) . This redundancy partly contributes to inefficiency of current therapeutic strategies. Modularity, another fundamental property of biological systems, provides an additional mechanism to localize perturbations to minimize the effects on the whole system (34) . Although generally robust, biological systems can also exhibit fragility at certain key points, attacks on which are destructive for the systems (35) . However, given the complexity of the human genome and the network that underlies the pathology, identifying the points of fragility is challenging. Our results demonstrates systems biology as a powerful tool to explore complex biological systems, which can help find the Achilles' heel of the pathological systems and design effective therapeutic strategies. showed that the SPP1 levels in the epithelium and stroma increased with the progression of clinicopathological stage. In normal epithelium, SPP1 was nearly undetectable (1). SPP1 was dispersed in hyperplastic epithelium but rarely detected in stromal cells (2) . For highly differentiated OSCC, SPP1 was detected in both tumor cells and stromal cells (3) . The positive staining was extended in infiltrated OSCC, with moderate to strong signal in the tumor invasion front (4). SPP1 was expressed strongly in both the tumor and its adjacent stroma for poorly differentiated OSCC (5) and OSCC with lymph node metastasis and recurrence within 3 years after surgery 
